Paid promotion. This report features Conexeu Sciences (Nasdaq: CNXU). Read the compensation and conflict disclosure before you decide how much weight to give our opinions. Not investment advice.

A free investor report · Longevity Markets Desk · October 2026

The *Longevity* Boom

Five ways to invest in living longer, and the one small-cap we think retail investors should research first.

Viking Schrödinger BioAge Capricor Conexeu

A market chart, or a pulse that keeps going. This report is about the companies betting on the second one.

Introduction

Wall Street Priced the Drug. Nobody Priced Dana.

Meet Dana. She isn't a real person. She's a composite of the patients doctors describe, and you have almost certainly met someone like her.

Dana is 54. Two years ago she started a GLP-1 weight-loss drug. She lost 50 pounds. Her blood pressure came down. Her jeans got loose. Everyone told her she looked great.

Then she looked in the mirror. Her cheeks had hollowed. Her skin looked loose. Her face looked older than it did before she got healthy.

Dana is not unusual. In July 2026, Gallup found that 11% of U.S. adults were currently taking a GLP-1 drug for weight loss, up from 3% just two years earlier. Fifteen percent had taken one at some point.[1] That's about one adult in nine. A systematic review in *Aesthetic Surgery Journal Open Forum* documents facial volume loss and skin changes after major GLP-1 weight loss.[2] People call it "Ozempic Face."

Now here's the part an investor should notice. When Eli Lilly's GLP-1 franchise took off, Lilly became the first healthcare company ever to reach a $1 trillion market value. It added nearly $700 billion in value between the end of 2022 and November 2025.[3] Wall Street priced the drug.

Almost nobody has priced Dana.

> *Wall Street priced the drug. Nobody priced what happens to the person taking it.*

Here's why that matters. McKinsey surveyed 174 U.S. providers in 2025 and found that 63% of GLP-1 patients seeking facial aesthetic treatment had no prior aesthetic history.[4] These aren't customers switching providers. They are brand-new customers, created by a drug.

That's one thread. Pull it and you find a much bigger story. Americans over 50 generated an estimated $12.5 trillion in economic activity in 2024, which AARP says is 43% of U.S. GDP and enough to rank as the world's third-largest economy. That figure is projected to nearly double to $24 trillion by 2060.[5] Everything that helps bodies work longer has a very large customer waiting.

This report walks through five doors into that market. We start where the money has already been made: the drugs that created Dana's problem. We end at the mirror, with the company we think is trying to solve it. In between you'll meet a software company that sells shovels, a biotech valued close to the cash in its bank account, and a lottery ticket with a lawyer attached.

OUR PROMISE, AND OUR PICK

We'll tell you what could go wrong with every name, including our favorite.

Especially our favorite.

Our favorite is Conexeu Sciences (Nasdaq: CNXU). It's also the riskiest stock in this report. Its own latest filing says there is "substantial doubt" it can continue as a going concern.[6] We still think it's the most interesting door, and we'll show you why. We'll also tell you what remains unproven. Read both.

The Big Picture

The Biggest Customer Base in History

$12.5T

economic activity by U.S. adults 50+ in 2024, headed to $24T by 2060[5]

$2.7T

U.S. health care spending by adults 50+ in 2024, projected to more than double by 2060[5]

11%

of U.S. adults currently taking a GLP-1 drug, up from 3% in two years[1]

63%

of GLP-1 patients seeking facial aesthetics were new to the category[4]

Think about what those numbers mean together. A huge, wealthy, aging population. A class of drugs that is changing how tens of millions of those people look. And a medical system that was built to treat disease, not to rebuild what rapid weight loss leaves behind.

MARKET	TODAY	PROJECTED	SOURCE
U.S. economic activity, adults 50+ (2024)	$12.5T	$24T by 2060	AARP[5]
Weight-loss drug market (2024)	about $15B	about $150B within 10 years	Morgan Stanley est., via Nasdaq[7]
Aesthetic injectables (2024)	$12.18B	$24.13B by 2030	Grand View Research[8]
Post-GLP-1 aesthetic restoration	about $0.7B	about $2B within five years	BCG[9]
Wound care devices	$2.6B (2023)	$4.2B by 2033	Market.us[10]

Different research firms size markets differently, and projections are estimates, not promises. Use these for scale, not precision.

THE NUMBER WORTH SITTING WITH

Lilly's two tirzepatide drugs, Mounjaro and Zepbound, did about $16.5 billion in combined sales in 2024.[11] That one pair of drugs helped push a company past a trillion dollars. The market for fixing what those drugs do to the face and body is about $0.7 billion today.[9] If the drug market really grows tenfold, how big does the aftermath get? Nobody knows. That is exactly the point.

Your Map: Five Doors Into Longevity

We ordered the doors by distance from Dana. Door One is the drug that caused the problem. Door Five is the mirror she's staring into. The further down the list, the smaller the company and the bigger the risk.

DOOR	THE BET IN ONE LINE	NEXT DATED CATALYST	BIGGEST RISK
1. The Challenger Viking (VKTX)	A better GLP-1 pill and injection	Oral Phase 3 starts, Q4 2026	Priced for perfection after a $548M raise
2. The Shovel Seller Schrödinger (SDGR)	Sells drug-discovery software to pharma	Bunsen full release, late 2026	Software revenue fell 10% in Q2 during a billing switch
3. The Clock BioAge (BIOA)	Aging-biology drugs, valued near cash	Phase 2 heart data, H2 2026	Novo's ZEUS failure hit the heart thesis
4. The Courier Capricor (CAPR)	Exosome platform riding an FDA decision	FDA decision, Nov. 22, 2026	Class action and a negative FDA panel vote
5. The Mirror Conexeu (CNXU)	A tissue-structure scaffold for the post-GLP-1 body	510(k) filing, targeted by Mar. 31, 2027	Going-concern doubt; about $2.0M cash at July 31, before a ~$5M private placement in October[57]

How every profile works

Each company gets the same four questions, in the same order, so you can compare them with each other and with anything already in your portfolio.

- **The bet in one line.** What are you actually betting on?
- **Why it could work.** The proof: numbers, partners, data and people, each with a source.
- **Next catalyst.** The next dated event that could move the stock.
- **What could go wrong.** Said plainly, every time, including for our favorite.

One more rule. When you see "our math" or "for illustration," that's arithmetic we did to give you a sense of scale. It is not a forecast and not a promise.

Door One

The Challenger

If Eli Lilly and Novo Nordisk are Coke and Pepsi, Viking Therapeutics is the upstart with a formula it says tastes better and lasts longer. And it's trying to get on the shelf next to them.

The shelf is worth fighting for. The weight-loss drug market did roughly $15 billion in 2024. Morgan Stanley thinks it could reach $150 billion.[7] Lilly's tirzepatide drugs alone did about $16.5 billion in 2024.[11] Viking has no product yet. It has a peptide called VK2735 and some numbers that got Wall Street's attention.

COMPANY TO RESEARCH

Viking Therapeutics · NASDAQ: VKTX

DOOR	LEAD DRUG	CASH (JUNE 30, 2026)
1. The Challenger	VK2735, dual GLP-1/GIP peptide	$502M, plus ~$548M net raised Sept. 2026

REVENUE

None

THE BET IN ONE LINE

If a next-generation GLP-1 can keep weight off with less frequent dosing, and a pill version works, Viking wins a slice of a market that could be ten times bigger than today.

WHY IT COULD WORK

- **The data pop.** A September maintenance study showed patients kept up to 97% of their weight loss on every-other-week dosing, and up to 90% on monthly dosing after the initial phase.[12]
- **It's in the late innings.** Both Phase 3 VANQUISH trials for the injectable version are fully enrolled, and a Phase 3 trial of an oral version is expected to begin in the fourth quarter of 2026.[13]
- **It's funded.** Viking held $502 million at June 30.[13] In September it raised about $548 million net by selling 9 million shares at $35 plus $258.75 million of 2% convertible notes.[14] That's roughly $1 billion before this quarter's spending, by our math.
- **The math is seductive.** Five percent of a $150 billion market is $7.5 billion a year. Viking's whole market value today is roughly $4 billion, by our math (about 125 million shares at about $33).[14,15] That's an illustration, not a forecast.

NEXT CATALYST

Start of the oral VK2735 Phase 3 trial, expected in Q4 2026.[13]

WHAT COULD GO WRONG

- **Zero revenue.** Q2 2026 net loss was $128.1 million, almost double the $65.6 million a year earlier.[15]
- **The September raise dilutes existing owners.** The stock fell for three straight sessions after it closed.[14] The convertible notes become shares if the stock climbs above roughly $50.75, which by our math could add about 5.1 million more.[14]
- Lilly and Novo aren't standing still, and a stumble in the oral program could hit a richly valued stock hard.

Door Two

The Shovel Seller

In every gold rush, the surest money tends to go to the people selling picks and shovels. In drug discovery, the shovel is software that predicts which molecules are worth building. Schrödinger sells it.

Why does that belong in a longevity report? Because every other door in this report starts with a molecule. Faster, cheaper discovery helps all of them. Schrödinger gets paid when pharma uses its tools, whether or not any single drug works.

COMPANY TO RESEARCH

Schrödinger · NASDAQ: SDGR

DOOR
2. The Shovel Seller

2025 REVENUE
$255.9M, up 23%

CASH AND SECURITIES
$418.8M (June 30, 2026)

PROFIT TARGET
Positive EBITDA by 2028

THE BET IN ONE LINE

AI makes every drug team faster. Schrödinger collects a toll on the road, and a few lottery tickets from its own drug programs.

WHY IT COULD WORK

- **Real revenue.** 2025 revenue grew 23% to $255.9 million, and the company holds $418.8 million in cash and securities.[16]
- **Customers are buying.** Q2 2026 annual contract value (ACV) grew 27% to $29.6 million, and total revenue rose 8% to $58.9 million.[17,18]
- **A new product with a big name behind it.** Schrödinger launched Bunsen, an AI "co-scientist," in early access and signed a Bristol Myers Squibb agreement to deploy it.[19]
- **Drug milestones add upside.** Management raised 2026 drug-discovery revenue guidance to $65–75 million after a $10 million milestone from Ajax Therapeutics.[18]

NEXT CATALYST

Bunsen's full release, which one analyst called critical, expected in late 2026.[20]

WHAT COULD GO WRONG

- Software revenue fell 10% in Q2 as customers shift to hosted licenses, which spread revenue over time. Software gross margin slipped to 71% from 76%.[17,18]
- One bearish read notes net dollar retention near 100% (from about 113%) and the count of high-value customers slipping from 29 to 27.[21]
- The stock has nearly tripled off its March low, so execution misses could hurt.[21] Drug-discovery revenue also depends on lumpy milestone payments.[20]

Door Three

The Clock

Most drug companies chase one disease at a time. BioAge Labs starts from a different idea: if you can target the biology of aging itself, one drug might help several age-related conditions.

On July 31, 2026, Novo Nordisk's heart-inflammation drug failed a major trial. BioAge's stock fell more than 60%, and Citi said the company's enterprise value, its market value minus the cash it holds, was nearing zero.[22] In plain English: for a moment, the market was valuing everything BioAge owns except its cash at about nothing.

COMPANY TO RESEARCH

BioAge Labs · NASDAQ: BIOA

DOOR
3. The Clock

CASH (JUNE 30, 2026)
$381.3M, runway through 2029

PARTNER
Novartis, up to $550M in deal value

MARKET CAP
~$443M (snapshot; moves daily)

THE BET IN ONE LINE

The market has marked down BioAge's heart-disease dream. You're betting the eye-disease program, the Novartis deal and a big cash cushion are worth more than the market thinks.

WHY IT COULD WORK

- **A cash cushion.** BioAge held $381.3 million at June 30 and says that funds operations through 2029.[23] At a market value near $443 million, you pay roughly $1.16 for each $1 of cash, per one data provider's snapshot.[24]
- **A real partner.** Novartis agreed to a deal worth up to $550 million ($20 million upfront plus up to $530 million in milestones).[25] It already produced $9.0 million of collaboration revenue in 2025.[26]
- **Data that got attention.** In Phase 1, BioAge's oral drug BGE-102 cut a key inflammation marker (hsCRP) by 85% at day 7 on the 60 mg dose.[27]
- **Near-term readouts.** Phase 2 heart-risk data (QUELL-CV) are expected in the second half of 2026, and diabetic macular edema (DME) data in mid-2027.[28]

NEXT CATALYST

QUELL-CV Phase 2 topline, expected in H2 2026.[28]

WHAT COULD GO WRONG

- Novo's ZEUS miss raised a hard question: does lowering inflammation markers actually protect hearts? William Blair called the approach high risk and difficult to build a thesis around.[29]
- Citi cut its price target to $21 from $52.[24] The stock traded between $4.25 and $25.95 over the past year.[28]
- BioAge has stumbled before: it discarded a Phase 2 obesity trial in late 2024.[29] Nothing in its pipeline is near the market.

Door Four

The Courier and the Courtroom

Your cells constantly mail tiny packages, called exosomes, to each other. Scientists hope to load those packages with medicine. It's a delivery system for the body, and it's wide open: the FDA's own safety notification says there are currently no FDA-approved exosome products.[30]

Capricor has an exosome platform called StealthX. In 2025 the FDA cleared its first test, a government-funded vaccine study.[31] But the stock doesn't trade on StealthX. It trades on a different product, a cell therapy called deramiocel, and an FDA decision due November 22. Think of it as a lottery ticket with a lawyer attached.

COMPANY TO RESEARCH

Capricor Therapeutics · NASDAQ: CAPR

DOOR	EXOSOME PLATFORM	BINARY EVENT
4. The Courier	StealthX (early clinical)	FDA decision, Nov. 22, 2026

Q2 2026 NET LOSS

$40.7M

THE BET IN ONE LINE

If the FDA approves deramiocel, Capricor becomes a commercial company with money to push StealthX forward. If it doesn't, the stock has already shown what can happen.

WHY IT COULD WORK

- **It's still alive.** After a 9-3 advisory committee vote against deramiocel's effectiveness, Capricor filed new data and a narrower indication, and the FDA extended its review to November 22, 2026.[32]
- **The market noticed.** Shares rose more than 157% in August, and Piper Sandler upgraded the stock to Overweight with a $25 target, up from $2.[33]
- **The platform is real, if early.** StealthX has an FDA-cleared IND and began a Phase 1 study funded by NIAID.[31]

NEXT CATALYST

FDA decision on deramiocel, due November 22, 2026.[32]

WHAT COULD GO WRONG

- **Whiplash.** The stock fell 64.5%, from $19.70 to $7.00, on July 27 when FDA briefing documents came out, then to $4.19 on July 30.[34] It was valued near $1.26 billion in March and about $544 million in late August.[35,36]
- **Lawsuits.** A securities class action alleges Capricor failed to disclose changes to the statistical plan for its Phase 3 trial. These allegations are unproven.[34]
- **History.** The FDA already issued a complete response letter in July 2025.[37] Thin exosome exposure: the decision on Nov. 22 is about a cell therapy, not StealthX. Treat this as speculation.

Door Five: Our Favorite

The Mirror

Dana's problem doesn't have a good fix yet. That's the opportunity. One small company thinks it has the missing piece: **Conexeu Sciences (Nasdaq: CNXU)**. It is developing an injectable liquid called Ten-Minute Tissue™, designed to give the body's own cells a scaffold to rebuild tissue.[38] It is still preclinical, and we'll be straight with you about what that means.

The problem Dana can't fix

About 90% of dermal filler is hyaluronic acid.[39] It works by swelling with water and typically lasts 6 to 12 months.[40] That's fine for a wrinkle. It isn't built to rebuild the structure a face loses when 50 pounds disappear.

Every fortune in aesthetics has been built on a different mechanism. Botox works on **muscle**. Fillers work on **volume**. Biostimulators (like Sculptra and Radiesse) work by **stimulation**, prompting a mild inflammatory response that leads the body to make collagen. Three mechanisms. Three multibillion-dollar categories.

The fourth mechanism is **structure**: giving the body's own cells something to build on.

> *Dr. Alan Scott has said he received about $4.5 million when he sold the rights to Botox in 1991. Botox Cosmetic did about $2.72 billion in 2024. AbbVie paid about $63 billion for the company behind it.*[41,42,43]

We are not saying Conexeu is Botox. Most new categories fail.

What Ten-Minute Tissue™ actually is

Picture a clear liquid in a syringe. Inject it, and in about ten minutes at body temperature it sets into a soft scaffold that resembles the body's own structural mesh, called the extracellular matrix.[*1][*7] According to the company, it is designed so the body's own cells can move in and support tissue restoration rather than scar.[38][*3][*9][*10]

The science comes out of more than a decade of work at a leading Canadian university, originally to help burn patients heal.[38] Conexeu says its patents are granted in the U.S., EU, Japan and Australia and that it owns the technology outright, with no royalties owed.[38]

Here's the honest label: it is preclinical and investigational. It has not been tested in humans.[38]

Nine reasons Conexeu deserves your research

1. **A customer base that didn't exist five years ago.** Gallup found that 11% of U.S. adults were taking a GLP-1 drug in July 2026.[1] McKinsey found that 63% of GLP-1 patients seeking facial treatment had no prior aesthetic history.[4] BCG sizes post-GLP-1 aesthetic restoration at about $700 million today, growing to about $2 billion within five years.[9]

2. **Today's tools weren't built for this.** About 90% of dermal filler is hyaluronic acid.[39] It works by swelling with water and typically lasts 6 to 12 months.[40] That's fine for a wrinkle. It isn't built to rebuild structure.

3. **A different mechanism.** Botox works on muscle. Fillers work on volume. Biostimulators work by prompting a mild inflammatory response. Ten-Minute Tissue™ is designed to give the body's own cells a scaffold to build on. Conexeu's own review of 43 FDA-cleared wound devices found none that offers a flowable, injectable, thermosensitive extracellular-matrix scaffold.[44] That is the company's analysis of public FDA records. It has not been independently verified.

4. **Science with a pedigree.** The technology comes out of more than a decade of research at a leading Canadian university.[38] Published papers from the researchers behind it report an in-situ forming skin substitute that improved healing in a hypertrophic scar model[45] and a flowable scaffold that sped wound closure in mice versus an untreated control and a collagen-based injectable.[46] Both are preclinical. Neither is a human trial.

5. **Technology the company says it owns outright.** Conexeu says its patents are granted in the U.S., EU, Japan and Australia, with no royalties owed.[38] If the device works, there is no licensor waiting for a cut.

6. **An operator team that has done this before.** CEO Miles Harrison is a former President and General Manager of Galderma North America and co-founded Novaestiq Corp.[47] Chief Medical Officer Dr. Brian Pilcher was Chief Scientific Officer of Suneva Medical, maker of Bellafill, whose product lines Tiger Aesthetics acquired in October 2024.[48] David Bogart became Chief Commercial Officer on June 15, 2026.[6] In aesthetics, the operator at the top often defines the franchise.

7. **A faster road than a drug.** Conexeu plans to seek clearance for its lead wound-care device through the FDA's 510(k) pathway, with a submission targeted by March 31, 2027.[6] The FDA clears roughly 3,000 to 3,500 devices a year this way.[49] A device route can be quicker than a drug approval. It is not a guarantee.

8. **One scaffold, five markets.** Aesthetic injectables, wound care, dental soft tissue, veterinary wound care and 3D bioprinting (sized separately in the table below). Conexeu has also started a preclinical program, B.R.E.A.S.T., a 3D-printed breast matrix, with the Wake Forest Institute for Regenerative Medicine.[50]

9. **Skin in the game, and buyers in the neighborhood.** A director and 10% owner reported buying about $162,000 of stock.[51] And big companies keep paying up for innovation. In 2025, J&J paid $14.6 billion for Intra-Cellular, Novartis about $12 billion for Avidity, and Merck $10 billion for Verona.[52] That doesn't mean Conexeu gets acquired. It describes the neighborhood.

One scaffold, five markets

MARKET	SIZE	PROJECTED	SOURCE
Aesthetic injectables	$12.18B (2024)	$24.13B by 2030	Grand View Research[8]
Wound care devices	$2.6B (2023)	$4.2B by 2033	Market.us[10]
Dental soft-tissue regeneration	$1.88B (2025)	$3.13B by 2035	Precedence Research[53]
Veterinary wound care	about $1.6B (2025)	$2.6B by 2032	VPA Research[54]
3D bioprinting	$1.6B (2023)	$6.5B by 2032	Global Market Insights[55]

What Still Needs to Be Proven

Like any early-stage device company, Conexeu has milestones still ahead. Ten-Minute Tissue™ has not yet been studied in people. The research above is preclinical, and none of the cited studies looked at the specific wound types the company plans to pursue first.[38] The next step is a 510(k) submission. The FDA may ask for additional data or testing, and it will decide whether the device is substantially equivalent to its identified predicate.[38] Reimbursement is worth understanding, too. Medicare now pays a flat rate per square centimeter for skin substitutes, so Conexeu will need to show its product fits within that framework.[56]

Competition is part of the picture. Established players such as Solventum, Integra and Smith & Nephew have sales forces, hospital contracts and clinical data that a young company is still building. The 0-of-43 format analysis is the company's own review of public FDA records and has not been independently verified.[44]

The milestone to watch is the 510(k) submission targeted for the first quarter of 2027, and any FDA questions that follow.[6]

OUR FAVORITE PICK

Conexeu Sciences · NASDAQ: CNXU

DOOR	STAGE	LEAD PRODUCT
5. The Mirror (our favorite)	Preclinical; not yet tested in people	Ten-Minute Tissue™, an injectable scaffold

NEXT CATALYST

510(k) filing, by Mar. 31, 2027

THE BET IN ONE LINE

Conexeu is trying to create the fourth mechanism in aesthetics, structure, at the exact moment tens of millions of people need it. If the FDA clears the device, a small company is aimed at billion-dollar markets. A wound-care clearance would not cover aesthetic use; aesthetics would need its own development and FDA authorization (the company has indicated a PMA pathway, estimated after 2030).[44] If it doesn't, the thesis stalls.

WHY IT COULD WORK

- A new category with a real, growing, newly created customer base.[1,4]
- A different mechanism from the fillers and wound products on the market today.[39,40]
- An operator team that has built and exited aesthetics businesses.[47,48]
- One scaffold aimed at five markets.[8,10,53,54,55]

NEXT CATALYST

510(k) submission targeted by March 31, 2027.[6]

WHAT COULD GO WRONG

- Still preclinical: not yet tested in people, and FDA clearance is not guaranteed.[38]
- Medicare's flat skin-substitute rate shapes what products in this space can earn.[56]
- Established competitors bring sales forces and hospital contracts.
- This report is paid promotion.

What Happens Next

The Catalyst Calendar

Stories are cheap. Dates are not. Here are the next dated events across all five doors. Put them in your calendar.

WHEN	WHO	WHAT	WHY IT MATTERS
Nov. 22, 2026	Capricor	FDA decision on deramiocel	Binary event; the stock has already swung wildly[32,34]
Q4 2026	Viking	Oral VK2735 Phase 3 begins	Tests whether a pill can match the injection[13]
H2 2026	BioAge	QUELL-CV Phase 2 topline	Heart thesis after Novo's miss[28]
Late 2026	Schrödinger	Bunsen full release	Product cycle behind the growth story[20]
By Mar. 31, 2027	Conexeu	510(k) submission	The gate to everything else; target already slipped once[6]
Mid-2027	BioAge	DME (eye disease) data	The program Citi still values[24,28]

Dates are company guidance or filings as of early October 2026 and can change.

The Bottom Line

Back to Dana

Remember Dana?

She's still standing in front of that mirror. The drug that helped her is a trillion-dollar story. The company that makes it is one of the most valuable on earth.[3] The fix for what it did to her face is, today, a $700 million question mark.[9]

That's the spine of this entire report. Wall Street priced the cause. We walked through the doors that lead from the cause to the cure.

- **The Challenger (Viking)** is where the money is being made right now, and where the valuation already assumes a lot of good news.
- **The Shovel Seller (Schrödinger)** gets paid whichever molecule wins.
- **The Clock (BioAge)** is a cash-backed bet on aging biology, wounded by Novo's miss.
- **The Courier (Capricor)** is a lottery ticket on November 22 with a lawsuit attached.
- **The Mirror (Conexeu)** is the one aimed directly at the problem that opened this report.

Four of these doors are bets on science that still has to work. One is a bet on a problem that already exists, in a customer base that already exists, and that people are already paying to address with products that weren't built for it.

That is why Conexeu is our favorite. It is also why you should be careful. It is tiny. It has no revenue. Its own filing says there is substantial doubt it can keep operating without new money. It raised about $5 million in October and may need to raise again before it files with the FDA.[57] In our opinion, a company with this much unmet need, this experienced a team, and this little left in the bank is a high-risk, high-uncertainty bet.

What would we do with this report? We'd put CNXU on a research list. We'd read the going-concern note in the 10-Q first.[6] We'd watch the next financing, because its price and size will matter more than any headline. And we'd watch the 510(k) date like a hawk.

The longevity boom is real. Whether it makes you money depends on which doors you walk through, how much you carry in with you, and whether you read the fine print. Dana can't wait for the science to catch up. The question for you is whether you want to be early, and whether you can afford to be wrong.

Please read

Important disclosure

PAID PROMOTION AND CONFLICTS OF INTEREST

Longevity Trader is not a securities dealer or broker, investment adviser or financial adviser, and you should not rely on the information in this report as investment advice. Conexeu Sciences Inc. has paid Longevity Trader 30,000 common shares in consideration for marketing services to be provided over a term of six months commencing June 1, 2026 and ending November 30, 2026. As of the date of this report, Longevity Trader owns 30,000 common shares of Conexeu Sciences Inc. We may sell these shares in the future, which creates a conflict of interest. Longevity Trader has received no compensation from, and holds no securities of, any other company named in this report.

NOT INVESTMENT ADVICE

This report is for informational and educational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any security, and it is not investment, legal or tax advice. It was not prepared with regard to your objectives, finances or needs. Consult a qualified, licensed financial adviser before making any investment decision.

HIGH RISK

Every company in this report is an early-stage or small-capitalization company. The securities of the companies we profile should be considered high risk. If you invest despite these warnings, you may lose your entire investment. Conexeu Sciences Inc. is a pre-revenue company whose latest quarterly

report states substantial doubt about its ability to continue as a going concern. Please do your own research, including reading each company's SEC filings, press releases and risk disclosures.

OPINION VERSUS FACT

Phrases such as "we think," "our favorite" and "in our opinion" are the publisher's opinions. They are not statements of fact and not guarantees of any outcome. Statements about a company's technology, data, plans and prospects reflect that company's own disclosures or third-party reporting and have not been independently verified by the publisher.

DATA, CALCULATIONS AND THE CHARACTER OF DANA

Prices, market values and financial figures are as of early October 2026 (some Viking, BioAge and Capricor figures are earlier, as dated in the text) and come from the third-party sources numbered in this report, including aggregator websites that may be delayed or contain errors. They change daily. Passages marked "our math," "for illustration" or "for scale" are the publisher's arithmetic, not forecasts. Market-research projections are estimates and vary widely by methodology. "Dana" is a hypothetical composite, not a real person or patient.

LEGAL PROCEEDINGS

Capricor Therapeutics is the subject of a securities class action. The allegations described in this report come from law-firm notices of the complaint; they are allegations only, are unproven, and the company may dispute them. Review the company's SEC filings for current status.

FORWARD-LOOKING STATEMENTS

This report includes statements that may be deemed forward-looking, including statements about regulatory timelines, clinical development, market sizes and business outlooks, including Conexeu Sciences Inc.'s anticipated PMA regulatory pathway and estimated market entry after 2030 for its aesthetics indication, often identified by words such as "expects," "plans," "anticipates," "believes," "targets," "estimates," "potential," "could" and "may." Such statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any will prove accurate.

PRECLINICAL STATUS

Conexeu Sciences Inc.'s CXU™ platform, including Ten Minute Tissue™, is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical, animal-model findings; clinical significance has not yet been established, and the device has not been submitted to or cleared/approved by the FDA for any use, in any indication. A wound-care clearance, if obtained, would not cover aesthetic use. There can be no assurance that the Company will obtain regulatory clearance or approval for any indication on any timeline, or at all.

TRADEMARKS

CXU™, B.R.E.A.S.T.™ and Ten Minute Tissue™ are trademarks of Conexeu Sciences Inc. Ozempic® is a registered trademark of Novo Nordisk A/S. BOTOX® is a registered trademark of Allergan, Inc., an AbbVie company. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Sculptra® and Restylane® are registered trademarks of Galderma. Radiesse® is a registered trademark of Merz North America, Inc. Bellafill® is a registered trademark of Suneva Medical, Inc. All other marks are the property of their respective owners, which are not affiliated with and have not endorsed Conexeu Sciences Inc. or this report.

Sources

Numbers in the text match the numbered sources below. Where a source has no public URL, the report is subscription or company material. Figures sourced to third-party aggregator pages may be delayed.

1. Gallup National Health and Well-Being Index (5,065 U.S. adults), July 2026, as reported by KFF Health News, "Pharma and Tech" morning briefing, July 8, 2026. https://kffhealthnews.org/morning-breakout/pharma-and-tech-070826/
2. Systematic review of facial and skin changes after GLP-1-related weight loss, Aesthetic Surgery Journal Open Forum, 2025, DOI 10.1093/asjof/ojaf056. https://academic.oup.com/asjopenforum/article/doi/10.1093/asjof/ojaf056/8160112
3. eMarketer, "GLP-1 boom makes Eli Lilly the first $1 trillion pharma company," November 2025. https://www.emarketer.com/content/glp-1-boom-makes-eli-lilly-first--1-trillion-pharma-company
4. McKinsey & Company, "GLP-1s are boosting demand for medical aesthetics," May 15, 2025 (survey of 174 U.S. medical spa, dermatology and plastic surgery providers). https://www.mckinsey.com/industries/life-sciences/our-insights/glp-1s-are-boosting-demand-for-medical-aesthetics
5. AARP, "The Longevity Economy Outlook 2026," developed by Economist Enterprise, June 2026. https://www.aarp.org/money/personal-finance/longevity-economy-report-2026 · https://insights.economistenterprise.com/health-society/the-longevity-economy-outlook-2026
6. Conexeu Sciences Inc., Form 10-Q for the quarter ended July 31, 2026, SEC EDGAR (financial statements, going-concern note, share counts, related-party and milestone disclosures). https://www.sec.gov/Archives/edgar/data/2066836/000106299326004935/form10q.htm
7. Nasdaq / Zacks, "Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in," November 2025 (weight-loss drug market about $15 billion in 2024; about $150 billion projected). https://www.nasdaq.com/articles/eli-lilly-hits-1-trillion-milestone-etfs-invest
8. Grand View Research, "Aesthetic Injectable Market Report" ($12.18 billion in 2024; $24.13 billion projected by 2030). https://www.grandviewresearch.com/industry-analysis/aesthetic-injectable-market-report
9. Boston Consulting Group, "Five Growth Imperatives for Medical Aesthetics in Times of Uncertainty," 2025 (post-GLP-1 aesthetic restoration spend about $700 million, growing to about $2 billion within

five years; medical aesthetics consumer market $63 billion in 2024 to about $97 billion by 2029). https://media-publications.bcg.com/Five-Growth-Imperatives-for-Medical-Aesthetics-in-Times-of-Uncertainty.pdf

10. Market.us, "Wound Care Devices Market" ($2.6 billion in 2023; $4.2 billion projected by 2033). https://market.us/report/wound-care-devices-market/

11. HealthDay News, "Eli Lilly Becomes First Trillion-Dollar Health Company," November 24, 2025 (Mounjaro $11.54 billion and Zepbound $4.93 billion in 2024 sales). https://www.orthoatlanta.com/health-news/eli-lilly-becomes-first-trillion-dollar-health-company

12. AlphaStreet, "Viking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Matters," September 2026. https://news.alphastreet.com/viking-therapeutics-vktx-vk2735-data-look-strong-but-cash-burn-still-matters/amp/

13. Viking Therapeutics, "Second Quarter 2026 Financial Results and Corporate Update," July 29, 2026 (cash and investments of $502 million at June 30, 2026; VANQUISH 1 and 2 fully enrolled; oral Phase 3 initiation expected 4Q26). https://ir.vikingtherapeutics.com/2026-07-29-Viking-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update

14. Stocktwits, "VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes," September 28, 2026 (9 million shares at $35; $258.75 million 2% convertible notes due 2032; shares at $33.03; up 29% year to date). https://stocktwits.com/news-articles/markets/equity/vktx-stock-548m-raise-closes-retail-dip-easy-buy-buyout-talks/cZMmVLGRBXo

15. GuruFocus, "Viking Therapeutics (VKTX) Q2 2026 Earnings Call Highlights" (Q2 2026 net loss $128.11 million, $1.10 per share, vs. $65.6 million a year earlier). https://www.gurufocus.com/news/8988878/viking-therapeutics-inc-vktx-q2-2026-earnings-call-highlights-advancing-obesity-pipeline-with-strong-cash-position-despite-rising-net-loss

16. Quartr, "Schrödinger (SDGR) Q2 2026 earnings summary" (cash and marketable securities of $418.8 million; 2025 revenue up 23% to $255.9 million; positive EBITDA targeted by 2028). https://quartr.com/events/schr-dinger-inc-sdgr-q2-2026_3eTj12w5

17. Schrödinger, Inc., "Schrödinger Reports Second Quarter 2026 Financial Results," Business Wire / BioSpace, August 5, 2026. https://www.biospace.com/press-releases/schrodinger-reports-second-quarter-2026-financial-results

18. GuruFocus, "Schrödinger (SDGR) Q2 2026 Earnings Call Highlights," August 2026 (ACV guidance $218–228 million; drug discovery revenue guidance raised to $65–75 million). https://www.gurufocus.com/news/9009674/schrodinger-inc-sdgr-q2-2026-earnings-call-

19. MarketBeat, "Schrodinger (NASDAQ:SDGR) Announces Quarterly Earnings Results," August 5, 2026 (Bristol Myers Squibb agreement for Bunsen; 75% hosted target by end of 2028; shares at $16.40). https://www.marketbeat.com/instant-alerts/schrodinger-nasdaqsdgr-announces-quarterly-earnings-results-2026-08-05/

20. Panabee, "Schrödinger Q2 2026: Navigating Software Transition and Milestone Dependency," August 2026. https://www.panabee.com/news/schrodinger-earnings-q2-2026-report

21. Walnut, "Is SDGR a Buy or a Sell? The Bull and Bear Case (2026)," September 2026 (net dollar retention near 100%; high-value customers 29 to 27; stock nearly tripled off its March low). https://walnutinvest.com/stocks/sdgr/is-it-a-buy-or-sell

22. Stocktwits, "BIOA, GLUE Stocks Clock Worst Day In Years: What's The NVO Connection?" August 2026 (shares fell more than 60%; Citi said enterprise value was nearing zero). https://stocktwits.com/news-articles/markets/equity/bioa-glue-stocks-clock-worst-day-in-years-what-s-the-nvo-connection/cZN4NtDRJSG

23. BioAge Labs, Inc., Form 8-K, second quarter 2026 results (cash, equivalents and marketable securities of $381.3 million at June 30, 2026; runway through 2029). https://www.sec.gov/Archives/edgar/data/0001709941/000119312526335368/bioa-ex99_1.htm

24. StockAnalysis.com, BioAge Labs (BIOA) quote page (market capitalization about $443 million; Citi price target lowered to $21 from $52). Snapshot at time of research; prices change daily. https://stockanalysis.com/stocks/BIOA

25. Fierce Biotech, "Novartis, BioAge take on age-related diseases in $550M pact," December 2024. https://www.fiercebiotech.com/biotech/novartis-and-bioage-take-age-related-diseases-new-550m-pact

26. BioAge Labs, Inc., Form 10-K for fiscal 2025, SEC EDGAR (Novartis collaboration revenue of $9.0 million in 2025). https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/bioa-20251231.htm

27. BioSpace, "Novo's late-stage IL-6 stumble shakes inflammation space," August 2026 (BGE-102 Phase 1: 85% hsCRP reduction at day 7 on 60 mg dose). https://www.biospace.com/drug-development/novos-late-stage-il-6-stumble-shakes-inflammation-space

28. RTTNews, "BioAge Labs Q2 Net Loss Expands; Expects QUELL-CV Phase 2 Results of BGE-102 in H2 2026," August 2026 (52-week range $4.25–$25.95; DME data anticipated mid-2027). https://www.rttnews.com/3676667/bioage-labs-q2-netloss-expands-expects-quell-cv-phase-2-results-of-bge-102-in-h2-2026.aspx

29. Webull / Benzinga, William Blair note on BioAge after the ZEUS result, August 2026. https://www.webull.ca/news-detail/15323075767460864

30. U.S. Food and Drug Administration, "Public Safety Notification on Exosome Products" (states there are currently no FDA-approved exosome products). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products

31. Capricor Therapeutics, Inc., Form 8-K, second quarter 2025 results (FDA clears IND for StealthX exosome-based vaccine; NIAID Phase 1 begins). https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001558370-25-011047/capr-20250811xex99d1.htm

32. Capricor Therapeutics, Inc., Form 8-K, August 24, 2026 (FDA extends deramiocel PDUFA date from August 22 to November 22, 2026 after a major amendment). https://www.sec.gov/Archives/edgar/data/0001133869/000110465926100071/capr-20260824xex99d1.htm

33. Stocktwits, "Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision," September 2026 (shares up more than 157% in August; Piper Sandler upgrade to Overweight, target $25 from $2). https://stocktwits.com/news-articles/markets/equity/why-capr-stock-rising-piper-sandler-upgrade-capricor-fda-deramiocel-dmd/cZsoiHdRuJt6

34. Bleichmar Fonti & Auld LLP, Capricor Therapeutics securities class action notice (class period December 17, 2025 to July 26, 2026; stock fell 64.5% from $19.70 to $7.00 on July 27, 2026, and to $4.19 on July 30 after a 9-3 advisory committee vote). Allegations are unproven. https://www.bfalaw.com/cases/capricor-class-action-lawsuit

35. MarketBeat, "Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2%," March 6, 2026 (market capitalization $1.26 billion). https://www.marketbeat.com/instant-alerts/capricor-therapeutics-nasdaqcapr-trading-up-62-heres-what-happened-2026-03-06/

36. Open Capital, "Capricor Therapeutics (CAPR) Q2 2026 earnings" (net loss $40.7 million; market cap $544 million as of August 27, 2026). https://www.opencapital.sh/stocks/capr/earnings/q2-2026

37. CGTLive, "FDA Extends Deramiocel Review for Duchenne Muscular Dystrophy," August 24, 2026 (July 2025 complete response letter; timeline). https://www.cgtlive.com/view/fda-extends-deramiocel-review-dmd

38. Conexeu Sciences Inc., Form S-1/A, filed March 4, 2026, SEC EDGAR (CIK 0002066836): company description, university origin, patents, Ten Minute Tissue, 510(k) strategy. https://www.sec.gov/Archives/edgar/data/2066836/000106299326001297/forms1a.htm

39. Roots Analysis, "Dermal Fillers Market" (hyaluronic acid about 90% of dermal filler market share). https://www.rootsanalysis.com/reports/dermal-fillers-market.html

40. U.S. Food and Drug Administration, "FDA-Approved Dermal Fillers" (hyaluronic acid fillers combine with water and swell; effect typically lasts about 6 to 12 months). https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers

41. FacialEsthetics.org, "Botox® Developer Regrets Missed Opportunity to Mint Money," citing Dr. Alan Scott's account of the 1991 sale of Oculinum (Botox) rights to Allergan for $4.5 million. facialesthetics.org

42. AbbVie, Inc., "AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results," Jan. 31, 2025 (Botox Cosmetic about $2.72 billion; Botox Therapeutic about $3.28 billion). news.abbvie.com

43. PharmaTimes, "AbbVie completes acquisition of Allergan" (about $63 billion). https://pharmatimes.com/news/abbvie_completes_acquisition_of_allergan_1340086/

44. Conexeu Sciences, corporate presentation posted at ir.conexeu.com ("Conexeu Corporate Deck," May 6, 2026), including "FDA KGN Device Review, 2026" (company analysis of 43 cleared wound devices, product code KGN, since 2020; none offers a flowable, injectable thermosensitive extracellular-matrix scaffold; company analysis of public FDA records, not independently verified) and the company's aesthetics regulatory pathway (PMA; estimated market entry after 2030). https://ir.conexeu.com/

45. Hartwell R., Poormasjedi-Meibod M.S., Chavez-Munoz C., et al., "An in-situ forming skin substitute improves healing outcome in a hypertrophic scar model," Tissue Engineering Part A, 2015;21(5):1085-1094 (preclinical). https://doi.org/10.1089/ten.tea.2014.0271

46. Pakyari M., Jalili R., Kilani R.T., et al., "Studying the in vivo application of a liquid dermal scaffold in promoting wound healing," Experimental Dermatology, 2022;31:715-724 (preclinical mouse study; not a human trial). https://pubmed.ncbi.nlm.nih.gov/34816490/

47. Conexeu Sciences, press release appointing Miles Harrison as President and CEO (prior roles at Galderma North America, Novaestiq Corp. and Castle Biosciences board). https://conexeu.com/conexeu-sciences-appoints-miles-harrison-as-president-chief-executive-officer-to-shape-the-future-of-true-tissue-regeneration/

48. Tiger Aesthetics, "Tiger Aesthetics Expands Regenerative Aesthetics Portfolio with Strategic Acquisition of Suneva Medical Product Lines," October 17, 2024. https://tiger-aesthetics.com/about/news/tiger-aesthetics-expands-regenerative-aesthetics-portfolio-with-strategic-acquisition-of-suneva-medical-product-lines/

49. RegDataLab, "FDA 510(k) Clearance Statistics: Medical Device Approval Trends" (about 3,000 to 3,500 510(k) clearances per year). https://www.regdatalab.com/blog/510k-clearance-analysis

50. Conexeu Sciences, "Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine," May 27, 2026. https://www.biospace.com/press-releases/update-conexeu-sciences-initiates-preclinical-development-program-for-b-r-e-a-s-t-bioregenerative-matrix-platform-with-wake-forest-institute-for-regenerative-medicine

51. Tiger Brokers, CNXU news feed (H.C. Wainwright initiation with $20 price target; director and 10% owner Lynn Sebastian Purcell reports $162,000 share purchase; warrant incentive program share issuance at $2.30), September 2026. https://www.itiger.com/stock/CNXU/news

52. bioXconomy, "Top 10 M&A Deals of 2025" (J&J/Intra-Cellular $14.6 billion; Novartis/Avidity about $12 billion; Merck/Verona $10 billion; Pfizer/Metsera up to $10 billion). https://www.bioxconomy.com/partnering/bioxconomy-s-top-10-m-a-deals-of-2025

53. Precedence Research, "Dental Soft Tissue Regeneration Market," 2026 ($1.88 billion in 2025; $3.13 billion projected by 2035). https://www.precedenceresearch.com/dental-soft-tissue-regeneration-market

54. VPA Research via MarketResearch.com, "Animal Wound Care" (about $1.6 billion in 2025; $2.6 billion projected by 2032). https://www.marketresearch.com/VPA-Research-v4245/Animal-Wound-Care-Size-Share-42060937/

55. Global Market Insights, "3D Bioprinting Market" ($1.6 billion in 2023; $6.5 billion projected by 2032). https://www.gminsights.com/industry-analysis/3d-bioprinting-market

56. BDO, "CMS Withdraws Prominent LCD for Skin Substitutes: What Healthcare Providers Need to Know" (flat Medicare payment of $127.14 per square centimeter for skin substitutes paid as incident-to supplies, effective January 1, 2026; biologics licensed under section 351 are excluded). https://www.bdo.com/insights/advisory/cms-withdraws-prominent-lcd-for-skin-substitutes-what-healthcare-providers-need-to-know

57. Conexeu Sciences, "Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors," Oct. 15, 2026; Form 8-K, Oct. 15, 2026. https://www.sec.gov/Archives/edgar/data/0002066836/000106299326005431/form8k.htm

Conexeu peer-reviewed publications (company bibliography)

[*1] Hartwell R., Leung V., Chavez-Munoz C., et al. A novel hydrogel-collagen composite improves functionality of an injectable ECM. *Acta Biomaterialia* (2011) 7; 3060-3069. https://doi.org/10.1016/j.actbio.2011.04.024

[*3] Hartwell R., Poursmasjedi-Meibod MS., Chavez-Munoz C., et al. An in-situ forming skin substitute improves healing outcome in a hypertrophic scar model. *Tissue Engineering Part A* (2015) 21(5); 1085-1094. https://doi.org/10.1089/ten.tea.2014.0271

[*7] Pourghadiri A., Alnojeidi H., Jalili R., et al. In situ forming nutritional and temperature sensitive scaffold improves the aesthetic outcome of meshed split-thickness skin grafts in a porcine model. *Advances in Wound Care* (2021) 10(3); 113-122.

[*9] Pakyari M., Jalili R., Kilani R.T., et al. Studying the in vivo application of a liquid dermal scaffold in promoting wound healing. *Experimental Dermatology* (2022) 31; 715-724.

[*10] Alnojeidi H., Kilani RT., Ghahary A. Evaluating the biocompatibility of an injectable wound matrix in a murine model. *Gels* (2022) 8, 49. https://doi.org/10.3390/gels8010049